Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2024 Jul 27

PMID 39062668

Authors

Zoha Kamali

Nafiseh Esmaeil

Chris H L Thio

Ahmad Vaez

Harold Snieder

Affiliations

Soon will be listed here.

Abstract

Objectives: Interleukin 6 (IL-6) levels at hospital admission have been suggested for disease prognosis, and IL-6 antagonists have been suggested for the treatment of patients with severe COVID-19. However, less is known about the relationship between pre-COVID-19 IL-6 levels and the risk of severe COVID-19. To fill in this gap, here we extensively investigated the association of genetically instrumented IL-6 pathway components with the risk of severe COVID-19.

Methods: We used a two-sample Mendelian randomization study design and retrieved genetic instruments for blood biomarkers of IL-6 activation, including IL-6, soluble IL-6 receptor, IL-6 signal transducer, and CRP, from respective large available GWASs. To establish associations of these instruments with COVID-19 outcomes, we used data from the Host Genetics Initiative and GenOMICC studies.

Results: Our analyses revealed inverse associations of genetically instrumented levels of IL-6 and its soluble receptor with the risk of developing severe disease (OR = 0.60 and 0.94, respectively). They also demonstrated a positive association of severe disease with the soluble signal transducer level (OR = 1.13). Only IL-6 associations with severe COVID-19 outcomes reached the significance threshold corrected for multiple testing ( < 0.003; with COVID-19 hospitalization and critical illness).

Conclusions: These potential causal relationships for pre-COVID-19 IL-6 levels with the risk of developing severe symptoms provide opportunities for further evaluation of these factors as prognostic/preventive markers of severe COVID-19. Further studies will need to clarify whether the higher risk for a severe disease course with lower baseline IL-6 levels may also extend to other infectious diseases.

References

Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei X . IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998; 101(2):311-20. PMC: 508569. DOI: 10.1172/JCI1368. View

Kamali Z, Vonk J, Thio C, Vaez A, Snieder H . A Mendelian randomization cytokine screen reveals IL-13 as causal factor in risk of severe COVID-19. J Infect. 2022; 85(3):334-363. PMC: 9126023. DOI: 10.1016/j.jinf.2022.05.024. View

Lousdal M . An introduction to instrumental variable assumptions, validation and estimation. Emerg Themes Epidemiol. 2018; 15:1. PMC: 5776781. DOI: 10.1186/s12982-018-0069-7. View

Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R . Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018; 9(1):224. PMC: 5768719. DOI: 10.1038/s41467-017-02317-2. View

Burgess S, Thompson S . Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015; 181(4):251-60. PMC: 4325677. DOI: 10.1093/aje/kwu283. View

Petrovas C, Yamamoto T, Gerner M, Boswell K, Wloka K, Smith E . CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest. 2012; 122(9):3281-94. PMC: 3428091. DOI: 10.1172/JCI63039. View

Del Giudice M, Gangestad S . Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018; 70:61-75. DOI: 10.1016/j.bbi.2018.02.013. View

Yang M, Wang C, Yang S, Leu C, Chen S, Wu C . IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep. 2017; 7:43829. PMC: 5338329. DOI: 10.1038/srep43829. View

Rosa M, Chignon A, Li Z, Boulanger M, Arsenault B, Bosse Y . A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. NPJ Genom Med. 2019; 4:23. PMC: 6754413. DOI: 10.1038/s41525-019-0097-4. View

10.

Gaziano L, Giambartolomei C, Pereira A, Gaulton A, Posner D, Swanson S . Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med. 2021; 27(4):668-676. PMC: 7612986. DOI: 10.1038/s41591-021-01310-z. View

11.

. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020; 28(6):715-718. PMC: 7220587. DOI: 10.1038/s41431-020-0636-6. View

12.

Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

13.

Gong B, Huang L, He Y, Xie W, Yin Y, Shi Y . A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther. 2022; 7(1):112. PMC: 8976167. DOI: 10.1038/s41392-022-00923-1. View

14.

Hemani G, Tilling K, Davey Smith G . Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017; 13(11):e1007081. PMC: 5711033. DOI: 10.1371/journal.pgen.1007081. View

15.

McFadyen J, Kiefer J, Braig D, Loseff-Silver J, Potempa L, Eisenhardt S . Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front Immunol. 2018; 9:1351. PMC: 6005900. DOI: 10.3389/fimmu.2018.01351. View

16.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

17.

Kerget F, Kerget B . Frequency of Interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) Polymorphisms in COVID-19 Patients in Turkey Who Develop Macrophage Activation Syndrome. Jpn J Infect Dis. 2021; 74(6):543-548. DOI: 10.7883/yoken.JJID.2021.046. View

18.

Bovijn J, Lindgren C, Holmes M . Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. Lancet Rheumatol. 2020; 2(11):e658-e659. PMC: 7518829. DOI: 10.1016/S2665-9913(20)30345-3. View

19.

Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams C, Walker S . Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022; 607(7917):97-103. PMC: 9259496. DOI: 10.1038/s41586-022-04576-6. View

20.

Sun B, Maranville J, Peters J, Stacey D, Staley J, Blackshaw J . Genomic atlas of the human plasma proteome. Nature. 2018; 558(7708):73-79. PMC: 6697541. DOI: 10.1038/s41586-018-0175-2. View